Compare WWW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WWW | TSHA |
|---|---|---|
| Founded | 1883 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2003 | 2020 |
| Metric | WWW | TSHA |
|---|---|---|
| Price | $24.75 | $3.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $25.80 | $13.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.5M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 96.55 | 5.56 |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $1,874,300,000.00 | $9,773,000.00 |
| Revenue This Year | $7.18 | N/A |
| Revenue Next Year | $5.95 | $6,389.64 |
| P/E Ratio | $17.85 | ★ N/A |
| Revenue Growth | 6.80 | ★ 17.28 |
| 52 Week Low | $14.00 | $3.46 |
| 52 Week High | $25.99 | $7.30 |
| Indicator | WWW | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 64.46 | 34.29 |
| Support Level | $18.65 | $3.46 |
| Resistance Level | N/A | $4.57 |
| Average True Range (ATR) | 1.30 | 0.28 |
| MACD | 0.28 | -0.03 |
| Stochastic Oscillator | 78.68 | 11.29 |
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; and Work Group. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear. Geographically, the company operates in United States; Europe, Middle East and Africa; Asia Pacific; Canada; and Latin America.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.